Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Compliance- Certificate Under Regulation 40(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

 With reference to Regulation 40(9) of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find attached herewith the certificate dated 14th April, 2021 received from M/s. Deep Shukla & Associates, Practicing Company Secretaries for the half year ended 31st March 2021. Kindly take the same on your records.
15-04-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Closure of Trading Window

 This is to inform you that pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time read with NSE Circular Reference no. NSE/CML/2019/11 and BSE Circular Reference no. LIST/COMP/01/2019-20, both dated 2nd April 2019, Trading Window for dealing in Securities of the Company will remain closed for Designated Persons of the Company and their immediate relatives with effect from Thursday, 1st April 2021 till 48 hours after the declaration of Audited Financial Results of the Company for the Financial Year ended 31st March 2021. The date of meeting of Board of Directors to approve the Financial Results of the Company for the Financial Year ended 31st March 2021 shall be informed in due course.
31-03-2021
Bigul

Kilitch Drugs India Ltd - 524500 - Resignation Of Internal Auditor

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that Ms. Rizwana Khan, Internal Auditor of the Company has resigned due to personal reasons. The company has accepted her resignation and relieved her from her responsibility. Her successor shall be appointed shortly and the same shall be intimated to Stock Exchange(s). Kindly take the same on your records.
19-03-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Change Of KMP- CS & CFO

 We wish to inform you that pursuant to Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. February 26, 2021, have 1.Considered and noted the resignation of Mr. Sujit Kumar Dash as the Chief Financial Officer of the Company with effect from February 28, 2021. 2.Considered and noted the resignation of Ms. Sunita Gohil as the Company Secretary of the Company with effect from February 28, 2021. 3.Considered & approved the appointment of Mr. Sunil S. Jain as the Chief Financial Officer of the Company with effect from 1st March 2021. 4.Considered and approved the appointment of Ms. Garima Trivedi as the Company Secretary & Compliance Officer of the Company with effect from 1st March 2021.
26-02-2021

Kilitch Drugs Consolidated December 2020 Net Sales at Rs 20.33 crore, up 27.61% Y-o-Y

 NULL
12-02-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Outcome Of Board Meeting Held On February 11, 2021

 Dear Sir/Madam, We wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. February 11, 2021, have Considered & approved the Un-audited financial results of the company for the quarter a ended December 31, 2020. In this connection please find enclosed the copy of Un-audited standalone & consolidated financial Results of the Company for the quarter ended December 31, 2020. along with Limited Review Report by the Statutory Auditors of the Company as 'Annexure-I'. The meeting commenced at 12:30 P.M. (IST) and concluded at 3:00 P.M.(IST) The above is for information and dissemination to the public at large.
11-02-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Intimation for Standalone And Consolidated Un-Audited Financial Result Of The Company For The Quarter Ended 31St December 2020

 KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2021 ,inter alia, to consider and approve We wish to inform you that the meeting of the Board of Directors of the Company will be held on Thursday, 11 February, 2021 at the Corporate Office of the Company at Mumbai at 12.30 A.M.: To Consider and approve the Standalone and Consolidated Un-audited Financial Result of the Company for the quarter ended 31st December 2020; Any other matter with the permission of the Chair. The above intimation is given to you pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015. Thanking You
04-02-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Shareholding for the Period Ended December 31, 2020

 Kilitch Drugs India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here
19-01-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Statement Of Investor Complaints For The Quarter Ended December 2020

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Sunita GohilDesignation :- Company Secretary and Compliance Officer
13-01-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith certificate issued by the Registrar & Share Transfer Agent M/s. Link Intime India Private Limited confirming the compliance of Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018. This is for your information and records.
08-01-2021
Next Page
Close

Let's Open Free Demat Account